We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RMD icon
26
ResMed
RMD
$28.9B
$42.8M 0.94%
165,802
– –
IDXX icon
27
Idexx Laboratories
IDXX
$44.8B
$41.1M 0.9%
76,548
-349
-0.5% -$167K
BHVN icon
28
Biohaven
BHVN
$2.32B
$39.5M 0.87%
2,802,853
+762,000
+37% +$13.6M
GEHC icon
29
GE HealthCare
GEHC
$28.7B
$38.2M 0.84%
515,468
-8,946
-2% -$623K
HCA icon
30
HCA Healthcare
HCA
$82.3B
$38M 0.84%
99,122
+37,315
+60% +$13.4M
CI icon
31
Cigna
CI
$74.5B
$36.6M 0.81%
110,712
-6,823
-6% -$2.2M
BPMC
32
DELISTED
Blueprint Medicines
BPMC
$36.5M 0.8%
+284,900
New +$29.6M
EWTX icon
33
Edgewise Therapeutics
EWTX
$4.28B
$36.4M 0.8%
2,775,997
+1,347,068
+94% +$19.4M
MRNA icon
34
Moderna
MRNA
$24.5B
$34.2M 0.75%
1,238,668
-279,454
-18% -$7.36M
VEEV icon
35
Veeva Systems
VEEV
$31.7B
$32.6M 0.72%
113,333
+83
+0.1% +$20.6K
ELV icon
36
Elevance Health
ELV
$80.9B
$31.9M 0.7%
82,053
+41,995
+105% +$16.9M
LLY icon
37
Eli Lilly
LLY
$1.05T
$31.9M 0.7%
40,920
-2,727
-6% -$2.12M
MCK icon
38
McKesson
MCK
$98.5B
$29.7M 0.65%
40,466
+9,886
+32% +$6.98M
ABBV icon
39
AbbVie
ABBV
$450B
$29.6M 0.65%
159,661
+24,421
+18% +$4.54M
ALGN icon
40
Align Technology
ALGN
$12.7B
$28.5M 0.63%
150,787
-206
-0.1% -$36.4K
RLAY icon
41
Relay Therapeutics
RLAY
$4.34B
$28.5M 0.63%
8,230,870
+853,578
+12% +$2.54M
PRCT icon
42
Procept Biorobotics
PRCT
$1.09B
$28.2M 0.62%
489,278
+74,355
+18% +$4.2M
DHR icon
43
Danaher
DHR
$144B
$27M 0.6%
136,811
+12,490
+10% +$2.42M
WVE icon
44
Wave Life Sciences
WVE
$1.12B
$26.6M 0.59%
4,094,458
– –
STE icon
45
Steris
STE
$21.2B
$26.4M 0.58%
109,887
– –
COO icon
46
Cooper Companies
COO
$14B
$25.3M 0.56%
356,074
-951
-0.3% -$72.8K
NTRA icon
47
Natera
NTRA
$38.9B
$24.9M 0.55%
147,491
+34,272
+30% +$5.34M
ZBH icon
48
Zimmer Biomet
ZBH
$17.6B
$24.4M 0.54%
267,716
-23,630
-8% -$2.28M
MOH icon
49
Molina Healthcare
MOH
$11.7B
$22.1M 0.49%
74,022
-1,873
-2% -$588K
GMED icon
50
Globus Medical
GMED
$10.5B
$19.6M 0.43%
332,336
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.